Barcelona: Arla Foods Ingredients has announced its latest innovation in high-protein, nutrient-dense application concepts specifically designed for users of GLP-1 anti-obesity medications. These new concepts will be showcased at the upcoming Vitafoods Europe event, scheduled to take place from May 5th to 7th, 2026, in Barcelona.

According to BERNAMA News Agency, GLP-1 receptor agonists, originally developed for diabetes treatment, have significantly influenced the weight management market. In 2025, 11% of consumers globally and 18% in the United States who were actively attempting to lose weight reported using these medications. The global uptake of GLP-1 receptor agonists is anticipated to rise further as their availability broadens, new tablet formats are introduced, and prices decrease.